The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 747
Primärprävention der koronaren Herzkrankheit
Mühleck, F., & Laufs, U. (2019) · Herz · doi:10.1007/s00059-019-04873-3 · Cited by 1
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.1.2023.1242 · Cited by 1
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1275 · Cited by 1
Zhang, R., Wang, Y., Peng, Y., Zhao, J., & Zhang, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1117143 · Cited by 1
Shao, Y., Liu, C., Zhuoma, D., Liu, Y., Liu, M., Zhaxi, P., Wang, J., Kou, X., & Xue, Z. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2534171 · Cited by 1
Plasma apolipoprotein A-I is a causal protective factor in sepsis
Campbell, K. R., Sitthikool, K., Genga, K. R., Takahashi, N., Zhu, P., Shimada, T., Nakada, T., Boyd, J. H., Russell, J. A., & Walley, K. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-19204-2 · Cited by 1
Yang, Y. S., Kim, S. Y., Seo, H., Lee, S., & Jung, K. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101323 · Cited by 1
Ali, S., Mansour, A., Sheraz, M., Ali, Z., Fatima, N. U. A., Hakim, Z., Sajid, U., Khattak, I. U., Fatima, A., Ali, F., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001086 · Cited by 1
Tao, B., & Zhang, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152958 · Cited by 1
Li, J., Guan, T., Zhu, D., Yang, W., Liu, Y., Gong, W., Liu, X., You, J., Feng, J., & Chen, X. (2025) · Acta Neurologica Scandinavica · doi:10.1155/ane/8831825 · Cited by 1
Genetic evidence supports therapeutic modulation of progranulin levels in Alzheimer’s Disease
Robins, C., Eicher, J. D., Liu, J., Lo, Y., Richardson, T. G., Western, D., Davitte, J., Cruchaga, C., Initiative, A. D. N., Kumar, U., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00011-y · Cited by 1
Residual coronary atherosclerotic risk and low LDL-cholesterol in chronic coronary syndromes
Neglia, D., Pane, K., Occhipinti, M., Gori, C. D., Rocchiccioli, S., Ragusa, R., Cavaliere, C., Zanfardino, M., Prontera, C., Botto, N., et al. (2026) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyag021 · Cited by 1
Luo, W., Xu, Y., Tao, Z., Sun, R., Li, X., Ji, Z., & Ma, G. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70411 · Cited by 1
Cardiovascular drug development: role of Mendelian randomization
Ciofani, J. L., Tybjærg‐Hansen, A., & Bhindi, R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag209 · Cited by 1
ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer
Boulay, G., Khodr, M., Bergeron, A.-C., Chong, E. W., Joncas, F., Castonguay, C., Robitaille, K., Hovington, H., Fradet, V., Bergeron, A., et al. (2026) · Cancers · doi:10.3390/cancers18071176 · Cited by 1
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
王, 茂. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1651984 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Zhang, W., Yoshiji, S., SLADEK, R. M., Dupuis, J., & Lu, T. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag087 · Cited by 2
More aggressive lipid lowering in people with diabetes?
Raal, F. J., & Mohamed, F. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30190-1 · Cited by 1
Complicações crônicas decorrentes do Diabetes mellitus: uma revisão narrativa de literatura
de Figueiredo, B. Q., Brito, A. C. V. S., Miranda, B. R. C., Lima, I. C. D. M., de Sousa, I. G., Sousa, L. G. V., do Vale, S., & de Souza, V. H. (2021) · Research Society and Development · doi:10.33448/rsd-v10i14.21794 · Cited by 1
Katzmann, J. L., Custodis, F., Schirmer, S. H., & Laufs, U. (2022) · Herz · doi:10.1007/s00059-022-05112-y · Cited by 1
PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
Pirillo, A., Tokgözoğlu, L. S., & Catapano, A. L. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v2i2.47 · Cited by 1
Self-citationPark, J. H., Lim, K.-T., Lee, J., Gil, Y. J., & Sung, J. (2024) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.24.671 · Cited by 1
Hsu, L., Teng, M., Duan, D., Yeh, K.-H., Wu, S., & Ko, Y. (2025) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_247_24 · Cited by 1
Hou, J., Lin, L., Huang, J., Chai, Q., Wang, S., Liu, X., & Liu, Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177838 · Cited by 2
Genetic Risk Score Enables a Vaccine for Early Primary Prevention of CAD
Roberts, R. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1617 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Inhibiteurs PCSK9 en pratique clinique : données et interrogations
Vergès, B. L., Dubois, C., & Legris, P. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.010 · Cited by 1
Management of Dyslipidemia after Stroke
Chang, Y., & Song, T. (2022) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2022.3.1 · Cited by 1
Will genetic studies deliver the next generation of cardioprotective therapies?
Nicholls, S. J., Ray, K. K., & Grobbee, D. E. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317690960 · Cited by 1
Cost Effectiveness of Nonstatin-to-Statin Therapy
Koh, K. K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.045 · Cited by 1
Koh, K. K. (2017) · Circulation · doi:10.1161/circulationaha.116.026821 · Cited by 1
Labos, C., Brophy, J. M., Smith, G. D., Sniderman, A. D., & Thanassoulis, G. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310907 · Cited by 1
Lower diabetes rate in patients with familial hypercholesterolaemia: What is the link?
Parhofer, K. G. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320903158 · Cited by 1
On the use of Mendelian randomization to assess the consequences of metformin exposure
Williams, D. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa058 · Cited by 1
Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteinsPreprint
Schmidt, A. F., Joshi, R., Gordillo‐Marañón, M., Drenos, F., Charoen, P., Giambartolomei, C., Bis, J. C., Gaunt, T. R., Hughes, A. D., Lawlor, D. A., et al. (2022) · medRxiv · doi:10.1101/2022.03.11.22272251 · Cited by 1
Wang, F., Mi, J., Bai, X., Ruan, G., Zhang, Y., & Yu, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1751879/v2 · Cited by 1
Prevention of Coronary Atherosclerosis
Figtree, G. A., Kott, K. A., & Vernon, S. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-25879-4_3 · Cited by 1
Li, H., Morze, J., Adiels, M., Kullberg, J., Merino, J., Sevilla-González, M. D. R., Bergström, G. M. L., Orho‐Melander, M., Söderberg, S., Östgren, C. J., et al. (2026) · medRxiv · doi:10.64898/2026.01.15.26344187 · Cited by 1
Predicting the benefits and risks of PCSK9 inhibition
Holmes, D. I. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.215
PCSK9 inhibition and the global diabetes epidemic
Mascitelli, L., & Goldstein, M. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4217-3
The shape of things to come in lipid management: a feast of reason
Watts, G. F., & Stroes, E. S. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000467
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Nichtmedikamentöse Therapie von Fettstoffwechselstörungen: Möglichkeiten und Grenzen
Saely, C. H., Gansch, R., & Drexel, H. (2018) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-018-0090-3
Starke Lipidsenkung für Diabetiker nach ACS besonders vorteilhaft
Pampel, S. L. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1348-7
Watts, G. F., & Stroes, E. S. G. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000560
PCSK9 inhibitors and diabetes: Translational biology to clinical practice
CHILTON, R. J., OLIVEROS, R. A., Gallegos, K. M., & Pham, S. V. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13600
Treating hypercholesterolaemia with evolocumab
Češka, R., Šnejdrlová, M., Vrablı́k, M., Altschmiedová, T., & Štulc, T. (2018) · Intervenční a akutní kardiologie · doi:10.36290/kar.2018.057
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke
Sullivan, D., Bonnitcha, P., Spinks, C., & Keech, T. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002247
Correctly understanding the diabetes data in FOURIER
Sabatine, M. S., Giugliano, R. P., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13812
Self-citationNovel Therapies for Dyslipidemia
Tafaj-Reddy, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88477
Tomlinson, B., Chan, P., Liu, Z., & Lam, C. W. K. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06951-9
The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease
윤창연 (2019) · YUHSpace (Yonsei University Medical Library)
Challenges in constructing genetic instruments for pharmacologic therapiesPreprint
Ference, B. A., Smith, G. D., Holmes, M. V., Catapano, A. L., Ray, K. K., & Nicholls, S. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.13115 · Cited by 1
Self-citationImproved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Dopheide, J. F., Adam, L., Wiedmer, S., Kaspar, M., Silbernagel, G., Baumgärtner, I., & Drexel, H. (2021) · Current Vascular Pharmacology · doi:10.2174/1570161119666210111123621
Gong, J., Asher, S. B., Cucchiara, B. L., Cuchel, M., & Soffer, D. E. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.006
Association of Low-Density Lipoprotein With All-Cause and Cause-Specific Mortality Among Us AdultsPreprint
Liu, Y., Liao, S., Wu, M., Xu, B., & Kang, L. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3931764
Cost-utility analysis of evolocumab in patients with ASCVD in Italy
Marcellusi, A., Bini, C., Rotundo, M. A., Arcangeli, E., Martínez, L., Vilela, F. S., & Mennini, F. S. (2021) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2021.2255
Genetic Contributions to Early and Late Onset Ischemic StrokePreprint
Jaworek, T. J., Xu, H., Gaynor, B. J., Cole, J. W., Rannikmäe, K., Stanne, T. M., Tomppo, L., Abedi, V., Amouyel, P., Armstrong, N. D., et al. (2021) · medRxiv · doi:10.1101/2021.11.06.21265795
New Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Clinical Dilemmas in Diabetes · doi:10.1002/9781119603207.ch17
Sejarah kebudayaan India Kuno / Anwar Sari
Sari, A. (1994)
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
(2016) · Nature · doi:10.1038/540173e
Wang, F., Mi, J., Bai, X., Ruan, G., Zhang, Y., & Yu, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1751879/v1
Xiao, Y., Zhou, G., Jing, D., Tang, Z., Peng, C., Kuang, Y., Zhu, W., Chen, X., Liu, H., & Shen, M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4135205
Targeted delivery of therapeutic oligonucleotides in pancreatic cancer
Iris, Y. (2022) · Journal of Biology and Medicine · doi:10.17352/jbm.000028
Session Three: Innovating Beyond Glucose Control in Diabetes Care
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10314488
Romandini, A., Baldassarre, D., Genovese, S., Capri, S., Pompilio, G., Scatigna, M., & Werba, J. P. (2023) · Pharmaceuticals · doi:10.3390/ph16020176
Specific Forms of Immune-Mediated Necrotizing Myopathies
Gaspar, B. L. (2023) · Springer eBooks · doi:10.1007/978-981-19-8421-1_5
Fujino, M., & Nicholls, S. J. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e14
Nicholls, S. J., & Nelson, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00029-7
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
Marston, N., & Sabatine, M. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00020-0
Self-citationEmerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics
Buyukkurt, A., & Harroud, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207773
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
Qiao, L., Lv, S., Meng, K., & Yang, J. (2024) · Clinical Rheumatology · doi:10.1007/s10067-023-06837-9
Additional file 1 of A phenome-wide association study of genetically mimicked statins
Li, S., & Schooling, C. M. (2021) · Figshare · doi:10.6084/m9.figshare.14880632
Borges, M. C., Haycock, P., Zheng, J., Hemani, G., Holmes, M. V., Smith, G. D., Hingorani, A. D., & Lawlor, D. A. (2022) · Figshare · doi:10.6084/m9.figshare.20057439
Luo, S., Lam, H. S., Chan, Y. H., Tang, C. S.-M., He, B., Kwok, M. K., Leung, G. M., Schooling, C. M., & Yeung, S. L. A. (2023) · Figshare · doi:10.6084/m9.figshare.24465040
Li, Z., Ye, C.-Y., Zhao, T., & Yang, L. (2020) · Figshare · doi:10.6084/m9.figshare.12586055
How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?
Chen, T., & Liu, N. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000934
The Role of Genomics in the Prevention of Cardiovascular Diseases
Wang, W. (2024) · International Journal of Molecular Medical Science · doi:10.5376/ijmms.2024.14.0010
Lee, D., & Voight, B. F. (2024) · medRxiv · doi:10.1101/2024.05.05.24306877
Genetically-Proxied Lower PAR1 and Renal Phenotypes: A Drug-Target Mendelian Randomization StudyPreprint
Tang, H., Gaunt, T. R., & Walker, V. M. (2024) · medRxiv · doi:10.1101/2024.08.08.24311690
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.09.001
Risk Signal Mining and Analysis of PCSK9 Inhibitors Based on FAERS DatabasePreprint
Peng, L., Xie, M., Feng, B., Pu, X., Zhang, Z., Fan, C. H., Li, C., & Wang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116760
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101523
Yang, B., Yao, B., Zou, Q., Li, S., Yang, S., & Yang, M. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3661739
Unravelling the benefits of nutraceutical seaweed Ecklonia to reaping its pharmaceutical approaches
Venkatachalapathi, S., Balasubramanian, B., Bhotla, H. K., & Mahomoodally, M. F. (2025) · Natural Resources for Human Health · doi:10.53365/nrfhh/203180
Rare biochemical & genetic conditions: clues for broader mechanistic insights
Mentis, A. A., & Dalamaga, Μ. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05652-6
Inhibitors of Epigenetic Modulators as Therapeutic Alternatives for Cardiovascular Diseases
Barraza, G. A., Rosales, W., & Meléndez, C. M. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575406970250919065317
Zhang, Y., Giovannucci, E. L., & Wang, D. D. (2025) · Diabetologia · doi:10.1007/s00125-025-06569-2
Cui, Y., Wang, Y., Wang, X., Liu, Y., Zhang, P., Hu, D., & Xiao, X. (2025) · International Journal of Genomics · doi:10.1155/ijog/2271298
Du, Z., Li, J., Liu, X., Zheng, Y., Liu, T., He, Y., Meng, Z., Wang, J., Zhao, D., Xue, D., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70374
Cardiovascular Risk Factor Dyslipidemia
Lebherz, C., & Lehrke, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-69938-6_9
Kajingulu, F.-P. M., Lepira, F. B., Nkodila, A. N., Makulo, J.-R. R., Mokoli, V. M., Ekulu, P. M., Bukabau, J., Nlandu, Y. M., Longo, A. L., N’seka, N., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19470301
Huang, J., 顾俊旭, Wang, K., Zhang, A.-M., Hong, T.-T., Li, S.-S., Yao, X.-Q., Yang, M., Yin, Y., Zhang, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26656591
Huang, J., 顾俊旭, Wang, K., Zhang, A.-M., Hong, T.-T., Li, S.-S., Yao, X.-Q., Yang, M., Yin, Y., Zhang, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26656588
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
